Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes

G. Széplaki, Róbert Szegedi, Kristóf Hirschberg, Tímea Gombos, L. Varga, I. Karádi, L. Entz, Zoltán Széplaki, Peter Garred, Z. Prohászka, G. Füst

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. Methods: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. Results: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. Conclusion: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalAtherosclerosis
Volume204
Issue number1
DOIs
Publication statusPublished - May 2009

Fingerprint

Complement Activation
Stroke
Carotid Artery Diseases
Brain Injuries
Animal Models
Brain

Keywords

  • C3a
  • C4d
  • C5b-5
  • Complement
  • Complement activation
  • Ischemic stroke
  • MBL
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. / Széplaki, G.; Szegedi, Róbert; Hirschberg, Kristóf; Gombos, Tímea; Varga, L.; Karádi, I.; Entz, L.; Széplaki, Zoltán; Garred, Peter; Prohászka, Z.; Füst, G.

In: Atherosclerosis, Vol. 204, No. 1, 05.2009, p. 315-320.

Research output: Contribution to journalArticle

Széplaki, G. ; Szegedi, Róbert ; Hirschberg, Kristóf ; Gombos, Tímea ; Varga, L. ; Karádi, I. ; Entz, L. ; Széplaki, Zoltán ; Garred, Peter ; Prohászka, Z. ; Füst, G. / Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. In: Atherosclerosis. 2009 ; Vol. 204, No. 1. pp. 315-320.
@article{b0bfc04fb0d348189c8817384fe9b951,
title = "Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes",
abstract = "Objective: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. Methods: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. Results: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. Conclusion: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.",
keywords = "C3a, C4d, C5b-5, Complement, Complement activation, Ischemic stroke, MBL, Stroke",
author = "G. Sz{\'e}plaki and R{\'o}bert Szegedi and Krist{\'o}f Hirschberg and T{\'i}mea Gombos and L. Varga and I. Kar{\'a}di and L. Entz and Zolt{\'a}n Sz{\'e}plaki and Peter Garred and Z. Proh{\'a}szka and G. F{\"u}st",
year = "2009",
month = "5",
doi = "10.1016/j.atherosclerosis.2008.07.044",
language = "English",
volume = "204",
pages = "315--320",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes

AU - Széplaki, G.

AU - Szegedi, Róbert

AU - Hirschberg, Kristóf

AU - Gombos, Tímea

AU - Varga, L.

AU - Karádi, I.

AU - Entz, L.

AU - Széplaki, Zoltán

AU - Garred, Peter

AU - Prohászka, Z.

AU - Füst, G.

PY - 2009/5

Y1 - 2009/5

N2 - Objective: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. Methods: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. Results: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. Conclusion: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.

AB - Objective: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. Methods: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. Results: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. Conclusion: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.

KW - C3a

KW - C4d

KW - C5b-5

KW - Complement

KW - Complement activation

KW - Ischemic stroke

KW - MBL

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=67349147890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349147890&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.07.044

DO - 10.1016/j.atherosclerosis.2008.07.044

M3 - Article

C2 - 18804761

AN - SCOPUS:67349147890

VL - 204

SP - 315

EP - 320

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -